Drugs · Dec 19, 2025

LiquidCapsule Manufacturing, LLC

8 extracted findings

FDA source excerpt, selected passage

Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).

Findings and supporting evidence

Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.

Findings extracted from the letter

Selected FDA passages, not the complete letter.

You failed to conduct adequate identity testing on incoming components used in the manufacture of your over-the-counter (OTC) drug products. For example, you failed to adequately test each shipment of each lot of **(b)(4)** for **(b)(4)**.

Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).

Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).

Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).

You failed to ensure that batch records are complete, and that all manufacturing activities and operations are recorded contemporaneously.

Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).

Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.

Sections and clauses cited

As cited in this historical letter, not a statement of current regulatory requirements.

21 CFR 211.84(d)(1)21 CFR 211.160(b)21 CFR 211.166(a)21 CFR 211.188 21 CFR 211.100(a)21 CFR 210

LiquidCapsule Manufacturing, LLC

Findings and supporting evidence

Findings extracted from the letter

Sections and clauses cited

More drug letters

Keep exploring

Put this kind of reading to
work on your own records.

FDA Warning Letter Alerts

Findings and supporting evidence

Findings extracted from the letter

Sections and clauses cited

More drug letters

Keep exploring

Put this kind of reading towork on your own records.

Put this kind of reading to
work on your own records.